Urinary liver type fatty acid binding protein in diabetic nephropathy
Open Access
- 30 May 2013
- journal article
- review article
- Published by Elsevier BV in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 424, 104-108
- https://doi.org/10.1016/j.cca.2013.05.020
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Roles of human liver type fatty acid binding protein in kidney disease clarified using hL‐FABP chromosomal transgenic miceNephrology, 2011
- Renal Liver-Type Fatty Acid Binding Protein (L-FABP) Attenuates Acute Kidney Injury in Aristolochic Acid NephrotoxicityThe American Journal of Pathology, 2011
- Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic PatientsDiabetes Care, 2011
- Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic PatientsDiabetes Care, 2010
- Urinary L‐FABP and anaemia: distinct roles of urinary markers in type 2 diabetesEuropean Journal of Clinical Investigation, 2010
- Urinary Excretion of Liver Type Fatty Acid Binding Protein Accurately Reflects the Degree of Tubulointerstitial DamageThe American Journal of Pathology, 2009
- Tubular and Glomerular Injury in Diabetes and the Impact of ACE InhibitionDiabetes Care, 2009
- Urinary Fatty Acids and Liver-Type Fatty Acid Binding Protein in Diabetic NephropathyNephron Clinical Practice, 2009
- Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathyClinical Nephrology, 2008
- Liver-Type Fatty Acid-Binding Protein Attenuates Renal Injury Induced by Unilateral Ureteral ObstructionThe American Journal of Pathology, 2006